BioWorld

Aug. 1, 2006

Predix In Potential $307.5M Collaboration With Amgen

In its first major partnership, Predix Pharmaceuticals Holdings Inc. could receive more than $307.5 million per terms of a new deal with Amgen Inc. on S1P1 modulators for autoimmune diseases. (BioWorld Today) Read More

YM Secures Japanese Partner For EGFR-Inhibitor In Cancer

Still Turning: Racial Profiling, Harassment, VC Execs Get Hip

Pandemic Planning: Not 'Out Of The Woods' Despite Good News

FDA Mulling Plan B OTC Sales For Those 18, Older

Opting For An LSE Listing, Napo Raises £11.9M In IPO

Receptor BioLogix Acquires Failed Aphton Cancer Drug

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 17, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for December 17, 2024.

Second insulin receptor offers new therapeutic avenues

BioWorld Science

Investigators at the Helmholtz Institute have shown that inceptor, an inhibitor of the insulin signaling pathway, acted by binding insulin and targeting it for...

Drug duo to Repare lack in gyno cancers? Phase I shows promise

BioWorld

Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

Mechanism underlying so-called idiopathic autism inception unveiled

BioWorld Science

Investigators at the Institute for Research in Biomedicine (IRB Barcelona) have unraveled how and why the absence of a neuronal microexon in cytoplasmic...